More MS news articles for Nov 2001

Randomized study of antibodies to IFN-g and TNF-a in secondary progressive multiple sclerosis|-2366265230036197976/-1052814329/6/7051/7051/7052/7052/7051/-1

Multiple Sclerosis,
October 2001,
vol. 7, no. 5,   pp. 277-284(8)
Skurkovich S. [1] *; Boiko A. [2]; Beliaeva I. [2]; Buglak A. [2]; Alekseeva T. [2]; Smirnova N. [2]; Kulakova O. [3]; Tchechonin V. [4]; Gurova O. [4]; Deomina T. [2]; Favorova O.O. [3]; Skurkovich B. [5]; Gusev E. [2]
[1] Advanced Biotherapy Laboratories, Rockville, MD, USA
[2] Department of Neurology and Neurosurgery, Russian State Medical University, Moscow, Russia
[3] Department of Molecular Biology and Biotechnology, Russian State Medical University, Moscow, Russia
[4] Immunochemical Laboratory of the Russian State Scientific Center of Social and Legal Psychiatry, Moscow, Russia
[5] Brown University Medical Center, Providence, Rhode Island, USA
[*] Correspondence: S Skurkovich, 802 Rollins Avenue, Rockville, MD 20852 USA


Studies of cytokines in multiple sclerosis (MS) have shown that immune mechanisms connected with disturbance of the synthesis of cytokines probably play critical roles in the initiation and prolongation of MS.

In a double-blind, placebo-controlled trial, 45 patients with active secondary progressive MS were randomized to three groups of 15 patients, each receiving a short course of antibodies to IFN-g, to tumor necrosis factor (TNF)-a, or a placebo.

After 12 months with analysis of disability (Expanded Disability Status Scale scores), accompanied by interval determinations of lymphocyte subpopulations, cytokine production levels, MRI, and evoked potentials, it was found that only patients who received antibodies to IFN-g showed statistically significant improvement compared to the placebo group a significant increase in the number of patients without confirmed disability progression.

This was supported by MRI data (a decrease in the number of active lesions) and systemic changes in cytokine status (a decrease in IL-1b, TNF-a, and IFN-g concentrations in supernatants of activated blood cells of these MS patients and an increase in TGF-b production).

Neutralization of IFN-g could be a new approach to treating secondary progressive MS.

Long-term administration of humanized monoclonal antibodies to IFN-g and simultaneous use of antibodies to IFN-g together with IFN-b products are planned.

© 2001 ingenta